Fairvalue-Calculator Fairvalue-Calculator
EN DE

Helix BioPharma Corp (HBPCF) Fair Value & Analysis

Healthcare · US · Market cap $131M

Price$1.71
Fair Value$0.6400
Upside-62.6%
Quality95/100
Evidence: Low Range $0.4800 – $0.8000

Fair value as of: Jun 24, 2026

Analysis

Helix BioPharma Corp (HBPCF) currently trades at $1.71, while our model-based Fair Value estimate is $0.6400 — implying the stock looks roughly 62.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Helix BioPharma Corp (HBPCF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.6400 versus a price of $1.71 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HBPCF?
Our 21-model fair value for Helix BioPharma Corp is $0.6400 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.71.
What is the quality score of HBPCF?
Helix BioPharma Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.